SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-22-000005
Filing Date
2022-01-07
Accepted
2022-01-07 08:03:50
Documents
14
Period of Report
2022-01-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20220107.htm   iXBRL 8-K 37509
2 EX-99.1 rvncjan2022corpupdateex991.htm EX-99.1 29584
6 rvnclogogifa.gif GRAPHIC 2149
  Complete submission text file 0001479290-22-000005.txt   215185

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20220107.xsd EX-101.SCH 1937
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20220107_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20220107_pre.xml EX-101.PRE 12542
8 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20220107_htm.xml XML 11389
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 22516502
SIC: 2834 Pharmaceutical Preparations